Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours

Pina Fusco(Città della Speranza Foundation), Gian Paolo Tonini(Città della Speranza Foundation)

BMC Cancer

October 21, 2019

10.1186/s12885-019-6149-4

Cited by 37

Related Papers

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

|Clinical Cancer Research|2014|99

Age‐dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma

|International Journal of Cancer|2012|57

miR-210-3p enriched extracellular vesicles from hypoxic neuroblastoma cells stimulate migration and invasion of target cells

|Cell & Bioscience|2023|14

Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

|Unknown|2023|0